HER2-Positive Cancer clinical trials
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
22 trials changed in the last 30 days: 1 stopped, 10 with notable changes, 11 with minor changes only.
- Notable: MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) Recruitment opened
- Notable: IAM1363 in HER2 Cancers Primary completion pushed from Dec 2027 to Oct 2028
- Notable: DB-Guide · T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd Start date pushed from Sep 18, 2026 to Nov 4, 2026
- Minor: EmpowHER 208 · Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy · HER2-positive Breast Cancer Trial sites expanded: 53 → 60 locations
- Notable: VRN101099 · HER2-Positive Solid Tumors Primary completion pushed from May 1, 2026 to Mar 1, 2027
- Minor: Pyrotinib, Trastuzumab Combined With Taxanes · Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC) Enrollment closed, study ongoing
- Stopped: Immune Response to Anti-HER2 Therapies · HER2-Positive Stage I-IV Breast Cancer Trial terminated
- Minor: NoCUT-BC · Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Primary and study completion pushed from Dec 31, 2027 to Jan 31, 2028
- Minor: Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable: At-Home Cancer Directed Therapy Versus in Clinic · Advanced Cancer Primary completion pushed from Jan 1, 2027 to Dec 1, 2027
- Minor: BREnnA · RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine · Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Trial sites expanded: 206 → 219 locations
- Minor: Measuring the Effects of Talazoparib · Advanced Cancer and DNA Repair Variations Study completion pushed from Jul 27, 2027 to Oct 22, 2027
- Minor: Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine · Metastatic HER2 Positive Breast Cancer Study completion pushed from Sep 29, 2026 to Sep 7, 2027
- Notable: SPECTACLE · Paclitaxel Polymeric Micelles Combined With HP and Adebelimab Versus Taxane Combined With HP as First-Line Treatment for Advanced HER2-Positive Breast Cancer Recruitment opened
- Minor: Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer Study completion pushed from Sep 25, 2026 to Aug 26, 2027
- Notable: DB-1303/BNT323 Versus T-DM1 in Breast Cancer Primary completion pushed from Feb 2026 to Dec 2027
- Notable: SuperHERO · Skipping Radiation Therapy · Breast Cancer Primary endpoint(s) modified
- Minor: Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast Cancer Start date pushed from Oct 2026 to Nov 2026
- Minor: NearWave Optical Molecular Monitoring Enrollment closed, study ongoing
- Notable: ZOLA · Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Start date pushed from Oct 1, 2026 to Nov 30, 2026
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New sponsor entrants, last 90 days sponsors with their first trial in this area
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-30 | NCT07907354 Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced… | Yunnan Cancer Hospital new | Phase 2 |
| 2026-10-21 | NCT07885683 MagSense® Human Epidermal Growth Factor Receptor 2 (HER2) Imaging Agent (MSH2IA) | Imagion Biosystems, Inc. new | Phase 1/2 |
| 2026-10-02 | NCT07856225 Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Fundación Santa Fe de Bogota new |
Active trials by phase
| Early Phase 1 | 3 | |
| Phase 1 | 17 | |
| Phase 1/2 | 30 | |
| Phase 2 | 112 | |
| Phase 2/3 | 6 | |
| Phase 3 | 48 | |
| Phase 4 | 5 |
Not charted: 68 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Top sponsors by active trials in this area
Fudan University (12) · Shanghai JMT-Bio Inc. (8) · Memorial Sloan Kettering Cancer Center (7) · Shu Wang (7) · Sichuan Baili Pharmaceutical Co., Ltd. (7) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (6) · Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Henan Cancer Hospital (5) · Jiangsu HengRui Medicine Co., Ltd. (5)
Get alerts when HER2-Positive Cancer trials change
Status changes, date slips, and new sponsor entrants: detected daily, delivered to your inbox.